Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2017-05-04

Clinical Trial Update: Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1 [Phase 2]

View source ↗

Summary

Phase 2 trial of buprenorphine/naloxone for heroin dependence and opioid-related disorders has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine/naloxone (buprenorphine/naloxone)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Heroin Dependence, Opioid-Related Disorders | Phase 2 | Status: WITHDRAWN